Humoral responses beyond major histocompatibility antigens continue to receive the attention of the transplantation community. We report on clinical studies testing clinical relevance of non-human leukocyte antigen (HLA) antigens in solid organ transplantation and provide an update on novel experimental findings. A conceptual framework on the role of graft microenvironment during initiation of non-HLA-related humoral immunity is addressed as well.
INTRODUCTION
Confirmation of clinical relevance for non-human leukocyte antigen (HLA)-related humoral responses paralleled by recent diagnostic developments and thorough mechanistic studies mirror intensive experimental and clinical research efforts in this area of transplant immunology. Several antigenic targets including two G-protein coupled receptors (GPCR); angiotensin type 1 receptor (AT 1 R) and endothelin type A receptor (ET A R), as well as intermediate filaments and extracellular proteins; collagen-V (Col-V), K-a1 tubulin (KA1T), and a bioactive C-terminal fragment of perlecan (referred to as LG3) are gaining in clinical importance. Non-HLA antibodies against these targets are more frequently autoantibodies, yet may also occur as alloantibodies. In this review we first provide an update of recent clinical studies based on the use of solid phase assays detecting the above-mentioned non-HLA antibodies in parallel with the corresponding experimental findings. We then discuss complex changes within the intragraft microenvironment, which may incite generation of non-HLA antibodies and facilitate their biologic actions. Finally, we propose how new developments in the area of non-HLA humoral immunity may translate into more comprehensive diagnostic approaches, which may lead to timely initiation of targeted therapies.
Angiotensin type 1 receptor and endothelin type a receptor Antibodies directed against AT 1 R and ET A R have been shown to be involved in both acute and chronic injury of kidney and heart allografts.
Kidney transplantation
The discovery path of AT 1 R antibodies spotlights the challenges surrounding functional non-HLA targets. AT 1 R antibodies were initially detected as activating IgG, which mimicked the actions of angiotensin II, a natural AT 1 R ligand in the functional bioassay that measures the increase in beating rate of cultured cardiomyocytes [1] . A standardized solid phase assay using sandwich ELISA methodology for detection of AT 1 R Abs in serum has been recently validated and established for testing transplant recipients and patients with autoimmune diseases [2, 3] . High levels of AT 1 R Abs at the time of transplant and diagnosis of antibody-mediated rejection (AMR) were found in patients with no HLA or major histocompatibility complex (MHC) class I-related chain A (MICA) DSA in a first cohort study employing solid phase assay [2] . The most recent prospective study conducted in 600 renal transplant recipients established the pretransplant positivity for AT 1 R Abs as an independent risk factor for graft loss [4] . Increased incidence of acute rejection, and in particular of AMR, was suggested as a link between AT 1 R Abs and inferior long-term graft survival [4] . Interestingly, some patients with pretransplant AT 1 R Abs also developed de-novo HLA-DSA implicating immunoregulatory functions of AT 1 R Abs. An interesting case of a new-onset collapsing focal segmental glomerulosclerosis in conjunction with AT 1 R Abs in the absence of HLA-DSA, which occurred after transplantation in a patient, who developed end-stage renal disease due to lupus nephritis was very recently reported [5 && ]. The expression of AT 1 R in podocytes, a major cellular determinant of glomerular filtration barrier [6] , suggests a possible involvement of AT 1 R Abs in other glomerular transplant pathologies. The role of AT 1 R Abs in pathogenesis of chronic AMR ( Fig. 1a and b) is currently being investigated in renal transplantation by several groups and the first data have demonstrated inferior outcomes for de-novo AT 1 R Abs and the most inferior outcomes in recipients who had developed AT 1 R Abs in conjunction with de-novo HLA-DSA [7] .
Heart transplantation
Systemic upregulation of AT 1 R as an antigenic target for humoral responses was found in donors with spontaneous intracerebral hemorrhage that was connected with subsequent development of cardiac allograft vasculopathy (CAV) [8] . Similarly, increased expression of AT 1 R was reported in hearts with recurrent vascular rejections and subsequent CAV [9] . ET A R also a member of GPCR family is expressed in the heart and lungs and upregulation of ET A R has been described in association with vasoconstriction, vasospasm and vascular remodeling [10, 11] . With the help of methodological lessons learned from the conformational nature of the target antigen for AT 1 R Abs, we have also established and introduced a solid phase assay, which can provide quantitative ET A R-Abs assessment and is feasible for routine clinical use [3] . Longitudinal assessment of AT 1 R Abs and ET A R Abs was attempted during the first posttransplant year in a pilot prospective study [12 && ]. Prevalence of HLA antibodies was very low in the whole cohort studied [12 && ]. Persistently, elevated levels of AT 1 R Abs and ET A R Abs strongly correlated with acute rejection, in particular AMR, earlier onset of microvasculopathy, and graft loss [12 && ]. Patients with higher levels of AT 1 R Abs and ET A R Abs also more frequently presented epicardial vasculopathy [12 && ]. The contribution of AT 1 R Abs and ET A R Abs to vascular obliteration is illustrated in Fig. 1b .
KEY POINTS
Studies based on the use of solid phase assays available for detection of non-HLA antibodies against AT 1 R, ET A R, K-a 1 tubulin, and collagen-V continue to confirm their clinical relevance in kidney, heart, and lung transplantation. Anti-perlecan antibodies emerge as a new target contributing to vascular allograft injury.
Widespread B-cell dysregulation is important feature of chronic humoral responses. Humoral non-HLA responses contribute to increased donor-specific HLA responses in the case of AT 1 R-Abs, and ET A R-Abs and donor-specific HLA responses enhance non-HLA autoimmunity against Col-V, KA1T, and perlecan.
A comprehensive diagnostic assessment strategies focusing on both HLA and non-HLA responses could improve risk stratification and lead to timely initiation of targeted therapies.
Collagen-V and K-a1 tubulin
The concept of induction of humoral and cell-mediated responses to intracellular and extracellular autoantigens originated a decade ago from studies conducted in heart and lung transplant recipients and was recently reviewed [13] . Col-V is a minor sequestered fibrillar collagen acting as an immunogenic extracellular matrix protein, in lung, skin and placenta. Col-V is expressed at typical locations where lung allograft rejection occurs, such as small airway epithelial cells, perivascular and peribronchial tissue. Like Col-V, KA1T, a gap junction intermediate filament cytoskeletal protein, which is also expressed on airway epithelial cells, was initially found as an antigen capable to induce humoral responses in lung transplantation, which facilitated bronchiolitis obliterans syndrome (BOS), a hallmark of chronic allograft rejection process [14] . Upon binding of antibodies to Col-V and KA1T, mechanisms that drive fibrogenesis are activated, implicating their direct role in BOS pathogenesis [14] (Fig. 1a ). Adoptive transfer of Col-V specific T lymphocytes replicated human BOS pathology in a rat lung isograft model and placed IL-17-dependent mechanisms into focus [15] . The most recent study, which evaluated the incidence of Col-V and KA1T Abs demonstrated a surprisingly common presence of both antibodies in 67% of studied lung transplant recipients [16 && ]. Higher pro-inflammatory cytokine concentrations ]. Antibodies against Col-V and KA1T may also be more frequently present in cardiac transplant recipients with AMR and CAV [17] . In this particular patient cohort, induction of IL-5 and IFN-g secreting self-antigen-reactive CD4 þ T cells with concomitant reduction in IL-10 lead to AMR, whereas a cytokine switch to the IL-17 pathway with a similar reduction in IL-10 leading to CAV [17] .
LG3 fragment of perlecan Perlecan is a proteoglycan embedded within the vascular basement membrane. Extracellular matrix (ECM) remodeling with proteolysis, which is closely associated with release of cryptic ECM fragments, referred to as matricryptins, happens during BM degradation [18] . The bone morphogenetic protein-1/tolloid family of metalloproteinases or cathepsin-L release the matricryptic angiostatic C-terminal fragments endorepellin and LG3 [19] . Endothelial cell apoptosis is crucial for the production of matricryptic fragments [20] . Thus, the contribution of LG3 in contexts in which endothelial apoptosis takes place, as for example in allograft vascular injury, is plausible. Exciting recent studies combining clinical and experimental design illustrate the involvement of perlecan fragment LG3 in the regulation of obliterative vascular remodeling associated with allograft rejection [21 && ]. Differences in the circulating levels of LG3 were compared between renal transplant patients with acute vascular rejection versus acute cellular rejection (n ¼ 16 in each group) in a retrospective case-control study employing modified immunoblotting capable of visualizing multimeric forms of serum proteins. Patients with vascular rejection had significantly higher LG3 levels, which were associated with decreased 6-months allograft survival when compared with the cellular rejection group [21 && ]. The recombinant murine LG3 was created by cloning and purifying the murine C-terminal LG3 fragment of domain V of perlecan and transfecting it into HEK cells in order to perform a passive transfer experiments of LG3 in a murine aortic transplant model [21 && ]. Increased neointima formation together with loss of endothelial cell layer in LG3 transduced mice confirmed direct pathophysiologic involvement of LG3 in obliterative allograft vasculopathy via impairment in endothelial repair and increase in promigratory and prosurvival phenotypes in vascular smooth muscle cells [21 && ] (Fig. 1b) . The group extended their efforts and reported that LG3 behaves as a neoantigen, which instigates generation of anti-LG3 antibodies, which were detected in pretransplant sera of patients with vascular, but not with cellular rejection [22 & ]. Passive transfer of human anti-LG3 antibodies into murine recipients of aortic allografts elicited similar vascular changes as were previously achieved when transfer of recombinant murine LG3 was used [21 && ,22 & ]. Passive transfer of anti-LG3 IgG induced only a modest increase in neointima formation in nonischemic allografts [22 & ]. In the ischemic allograft the extent of vascular changes was striking as shown by dense NK cell infiltration, C4d deposition and pronounced obliterative changes [22 & ]. Analysis of larger prospective cohorts is however necessary to confirm the promising results of these two pilot studies.
Tolerance check-points and role of intragraft microenvironment Breakdown of B-cell self-tolerance is emerging as one of the central features accompanying chronic rejection. Widespread B-cell dysregulation has been documented in renal transplant recipients with chronic humoral rejection [23] . Only minimal overlap in antigenic targets between patients was found, implicating that each patient had developed autoantibodies to a unique set of antigens [23] . Moreover, a wide range of autoantigens was detected in 'omics studies implicating that autoimmunity is not only triggered by specific recognition of many autoantigens but may instead represent a broad autoimmune response to the transplant process itself [24] . The current concept is that loss of tolerance to autoantigens occurs in a stepwise process within intragraft tertiary lymphoid tissue [25] . Polyclonal circulating autoantibodies were found in one-third of renal transplant recipients with terminal chronic rejection [26 & ]. Failure of intragraft immunoregulation is precipitated by changes within the microenvironment, which interferes with peripheral deletion of autoreactive immature B cells [26 & ]. Translocation of intracellular antigens to apoptotic bodies or extracellular space may enhance antigen recognition and initiate autoimmune response [27] . Presentation of target antigens to the immune system may then induce an autoimmune response that is further precipitated in various conditions of cellular stress. Inflammatory events induced either by ischemia or inflicted by anti-HLA Abs might lead to de-novo expression of autoantigens and later loss of tolerance [28] . In most cases, autoantibodies to intracellular antigens are generated de novo. The activation of the alloimmune response leads to the generation of Th17 cells, production of IL-17 and increased autoimmunity against self antigens. Antibody-induced autoimmunity towards intermediate filaments and extracellular antigens in lung transplantation has been recently reviewed in great detail [27] [28] [29] and includes an analysis of complex intersections between alloimmunity and autoimmunity.
Mechanisms of tolerance loss to AT 1 R and ET A R differ from those responsible for autoimmunity against intermediate filaments. Unlike other non-HLA antibodies, AT 1 R Abs and ET A R Abs are beyond transplant context directly involved in pathophysiology of autoimmune vascular disease of pregnancy -pre-eclampsia and, most severely, autoimmune vasculopathy in human pathology and systemic sclerosis [3, 30] . Epitopes for AT 1 R Abs in transplant and pre-eclamptic patients are directed against amino acids contained within the second extracellular loop (ECL2) of the receptor, which implies that mechanisms of sensitization differ from those described for neoantigens. Responses related to genetic factors [31] or ischemic injury [32] , which may upregulate expression of AT 1 R and ET A R, may represent decisive modulators of strength of antibody responses.
THERAPEUTIC IMPLICATIONS
AT 1 R Abs and ET A R Abs are directed against GPCRs, which represent, in the case of AT 1 R, one of the most successful cardiovascular targets of modern drug therapies. Pharmacologic antagonists at the ET A R are approved for treatment of pulmonary arterial hypertension and currently tested for other renal and cardiac conditions. Extracorporeal strategies based on rapid and effective reduction of antibody titres using plasmapheresis or immunoadsorption known in therapies of HLA-AMR are applicable in the area of AT 1 R Ab-related acute pathologies. Such combined pharmacologic and antibody removal therapeutic approachs rescued renal allografts in the proof of concept study [1] . A similar strategy was efficient in pediatric renal transplant patients and a patient with collapsing focal segmental glomerulosclerosis (FSGS) [5 && , 31, 33] . Therapeutic targeting of antibodies against neoantigens seems to be more challenging, as Col-V Abs and KA1T Abs persisted after classical anti-humoral interventions.
CONCLUSION
Accumulating data suggest that predicting a given patient's clinical outcome on the basis of HLA presensitization alone is insufficient. This applies to patients without an apparent immunological risk before transplantation as well as to patients with HLA presensitization. The detection of AT 1 R Abs and ET A R Abs in kidney and heart transplant recipients and Col-V and KA1T antibodies in lung recipients is justified according to the available data, which raises the prospect of improving routine immunological risk stratification.
